ArticleHuman vaccines & immunotherapeutics2026
Maximizing public health benefits: Policy perspectives on coverage and cell-based influenza vaccines in the US.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-based influenza vaccines can increase vaccine effectiveness by avoiding egg adaptations associated with traditional egg-based manufacturing techniques. This study evaluated the impacts of switching from use of an egg-based trivalent influenza vaccine (TIVe) to a cell-based vaccine (TIVc) for vaccination of individuals <65 y of age in the US. We used a dynamic age-stratified susceptible-exposed-infectious-recovered model combined with an age-structured decision tree model to compare the health and economic impacts of using TIVc in individuals <65 y combined with adjuvanted trivalent influenza vaccine (aTIV) in older adults (≥65 y) with two baseline scenarios: 1. vaccination of all individuals with TIVe; 2. vaccination of individuals <65 y with TIVe and ≥65 y with aTIV. Use of TIVc+aTIV resulted in substantial reductions in influenza burden across all vaccine coverage levels evaluated, with 8.5 million cases, 127,000 hospitalizations, and 19,000 deaths averted compared with TIVe at 65% coverage. The combination of TIVc and aTIV was cost-saving compared with either baseline scenario, irrespective of vaccine coverage level. Analysis by age group showed that TIVc+aTIV was either cost-effective or cost-saving across all pediatric and adult age groups, with greatest direct cost benefits seen in adults 50-64 y. Overall, our findings support the preferential use of TIVc over TIVe in individuals <65 y in vaccination programs, along with inclusion in programs together with an enhanced vaccine in adults ≥65 y.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.